menu
    • menu

    Company profile for Relmada Therapeutics

    NEW Drugs in Dev: 4
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage...
    Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage our considerable industry and development experience, and disease knowledge to identify, develop and commercialize product candidates for CNS conditions with high unmet needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Relmada TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Relmada Therapeutics, Inc. 880 Third Avenue 12th Floor New York, NY 10022
    Telephone
    Telephone
    646-876-3459
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.relmada.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/relmada-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/relmada?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Relmada Therapeutics Unveils Q1 2026 Financials And Business
    Relmada Therapeutics Unveils Q1 2026 Financials And Business

    12 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/12/3293401/0/en/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update.html

    GLOBENEWSWIRE
    12 May 2026
    Share Share
    Relmada Therapeutics Reports Q1 2026 Results on May 12
    Relmada Therapeutics Reports Q1 2026 Results on May 12

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288667/0/en/relmada-therapeutics-to-report-first-quarter-2026-financial-results-on-tuesday-may-12-2026.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Relmada Therapeutics To Present NDV-01 Abstracts At AUA2026
    Relmada Therapeutics To Present NDV-01 Abstracts At AUA2026

    05 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7271611

    FIRSTWORD PHARMA
    05 May 2026
    Share Share
    Relmada Therapeutics Reports 2025 Results And Business Update
    Relmada Therapeutics Reports 2025 Results And Business Update

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3259417/0/en/Relmada-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Relmada Therapeutics To Release Q4 2025 Financial Results
    Relmada Therapeutics To Release Q4 2025 Financial Results

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254447/0/en/Relmada-Therapeutics-to-Report-Fourth-Quarter-2025-Financial-Results-on-Thursday-March-19-2026.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Relmada Therapeutics Unveils 12-Month Phase 2 Interim Data
    Relmada Therapeutics Unveils 12-Month Phase 2 Interim Data

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251681/0/en/Relmada-Therapeutics-Reports-12-Month-Phase-2-Interim-Data-for-NDV-01-in-Non-Muscle-Invasive-Bladder-Cancer.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search